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Summary
Background Gastrostomy feeding is commonly used to support patients with amyotrophic lateral sclerosis who 
develop severe dysphagia. Although recommended by both the American Academy of Neurology and the European 
Federation of Neurological Societies, currently little evidence indicates the optimum method and timing for 
gastrostomy insertion. We aimed to compare gastrostomy insertion approaches in terms of safety and clinical 
outcomes.
Methods In this large, longitudinal, prospective cohort study (ProGas), we enrolled patients with a diagnosis of 
deﬁ nite, probable, laboratory supported, or possible amyotrophic lateral sclerosis who had agreed with their treating 
clinicians to undergo gastrostomy at 24 motor neuron disease care centres or clinics in the UK. The primary outcome 
was 30-day mortality after gastrostomy. This study was registered on the UK Clinical Research Network database, 
identiﬁ cation number 9923.
Findings Between Nov 2, 2010, and Jan 31, 2014, 345 patients were recruited of whom 330 had gastrostomy. 163 (49%) 
patients underwent percutaneous endoscopic gastrostomy, 121 (37%) underwent radiologically inserted gastrostomy, 
43 (13%) underwent per-oral image-guided gastrostomy, and three (1%) underwent surgical gastrostomy. 12 patients 
(4%, 95% CI 2·1–6·2) died within the ﬁ rst 30 days after gastrostomy: ﬁ ve (3%) of 163 after percutaneous endoscopic 
gastrostomy, four (3%) of 121 after radiologically inserted gastrostomy, and three (7%) of 43 after per-oral image-
guided gastrostomy (p=0·46). Including repeat attempts in 14 patients, 21 (6%) of 344 gastrostomy procedures could 
not be completed: 11 (6%) of 171 percutaneous endoscopic gastrostomies, seven (6%) of 121 radiologically inserted 
gastrostomies, and three (6%) of 45 per-oral image-guided gastrostomies (p=0·947). 
Interpretation The three methods of gastrostomy seemed to be as safe as each other in relation to survival and 
procedural complications. In the absence of data from randomised trials, our ﬁ ndings could inform clinicians and 
patients in reaching decisions about gastrostomy and will stimulate further research into the nutritional management 
in patients with amyotrophic lateral sclerosis.
Funding Motor Neurone Disease Association of Great Britain and Northern Ireland (MNDA) and the Sheﬃ  eld 
Institute for Translational Neuroscience (SITraN).
Copyright © ProGas Study Group. Open Access article distributed under the terms of CC BY.
Introduction
Amyotrophic lateral sclerosis is a neurodegenerative 
illness causing progressive weakness and wasting of 
muscles controlling movement, breathing, and swallow-
ing.1 Dysphagia is a common problem in patients with 
amyotrophic lateral sclerosis and causes diﬃ  culties in 
maintaining a safe and adequate oral intake of nutrition 
and ﬂ uids.2 Patients with severe dysphagia often experience 
weight loss, choking, and coughing on attempting to 
swallow, episodes of aspiration, and prolonged and 
eﬀ ortful mealtimes.3–6
Gastrostomy feeding is recommended to provide long-
term nutritional support for patients with amyotrophic 
lateral sclerosis with severe dysphagia.7 Three main 
methods of gastrostomy insertion are currently used 
in patients with amyotrophic lateral sclerosis: percu-
taneous endoscopic gastrostomy, radiologically inserted 
gastrostomy, and per-oral image-guided gastrostomy.8 
However, with little evidence available,9,10 current practice 
in relation to choice of method and timing of gastrostomy 
insertion is largely based on consensus and expert 
opinion.8 Gastrostomy could be beneﬁ cial for the survival, 
quality of life, and nutritional outcome of patients with this 
disease, but there is a paucity of high-quality evidence 
relating to these aspects of the intervention.9,11–13
In response to the paucity of evidence and calls by 
organisations such as the American Academy of 
Neurology and the European Federation of Neurological 
Societies for more evidence to guide clinicians and 
optimise standards of care,7,14 we aimed to identify the 
optimum gastrostomy timing and insertion method in 
terms of safety and clinical outcomes.
Methods
Study design and participants
In this large, multicentre, longitudinal, prospective 
cohort study (ProGas), we enrolled patients with a 
diagnosis of deﬁ nite, probable, laboratory supported, or 
For the ProGas study protocol 
see http://sitran.dept.shef.ac.
uk/clinical-studies/progas
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possible amyotrophic lateral sclerosis (as deﬁ ned by the 
El Escorial criteria),15 who had agreed with their clinicians 
to undergo gastrostomy at one of 24 motor neuron disease 
care centres or clinics in the UK (21 in England, two in 
Scotland, and one in Northern Ireland). Patients who had 
been diagnosed with a disorder characterised by cognitive 
impairment, such as fronto temporal dementia, were 
excluded. Patients were approached and invited to take 
part in the study by a member of the research team when 
a decision had been made to refer the patient for a 
gastrostomy insertion. Ethical approval was granted by 
the National Health Service NRES Leeds (Central) 
Research Ethics Committee and applied to all participating 
care centres or clinics. Informal carers, such as family 
members, of patients who had accepted to take part in the 
study were also invited to participate. All participants who 
agreed to take part in the study provided written informed 
consent before data collection.
Procedures
Adhering to the study protocol and the National Institute 
for Health Research guidelines for good clinical practice, 
data collection was carried out by experienced members of 
the local research teams. Data were collected at four 
timepoints: at the time of recruitment (baseline), at the 
end of the gastrostomy procedure, at 3 months after 
gastrostomy, and at 12 months after gastrostomy. At 
baseline, we collected the following information: demo-
graphic characteristics; clinician opinion on indication, 
timing, potential beneﬁ ts, and preferred type of 
gastrostomy; patient’s inﬂ uence on the timing of 
gastrostomy; measures of respiratory function; and indices 
of disease progression. At baseline, 3 months, and 
12 months we collected the following information: demo-
graphic characteristics, weight, height, and score on the 
revised amyotrophic lateral sclerosis functional rating 
scale (ALSFRS-R).16 Data related to the operation itself 
such as gastrostomy equipment, type of gastrostomy tube 
used, procedure length, and details of any complications 
were collected at the end of the gastrostomy procedure. At 
baseline and 3 months after gastrostomy insertion, 
patients who gave consent were asked to complete a 
questionnaire assessing quality of life (MQOL)17 and a 
questionnaire assessing the strain of caregiving activities 
was completed by consenting informal carers (MCSI).18
Outcomes
The primary outcome of the study was 30-day mortality 
after gastrostomy.8 The secondary outcomes were 
perigastrostomy and post-gastrostomy complication rate 
(deﬁ ned as complications that occurred during the 
gastrostomy procedure and those that occurred at any 
timepoint in the ﬁ rst 3 months after completion of the 
gastrostomy insertion procedure, respectively), median 
survival time from gastrostomy placement, nutritional 
status change, self-perceived quality of life changes after 
gastrostomy, and changes in carer strain after 
gastrostomy.
Research in context
Evidence before this study
We searched PubMed, Embase, The Cochrane Library, and ISI Web 
of Knowledge for reports published before July 1, 2010, combined 
with citation searching and reference chaining, using the 
keywords: “motor neuron* disease” or “MND”, “amyotrophic 
lateral sclerosis” or “ALS”, “gastrostomy”, “percutaneous 
endoscopic gastrostomy” or “PEG”, “radiologically-inserted 
gastrostomy” or “RIG”, “per-oral image-guided gastrostomy” or 
“PIG”, “timing”, “mortality”, “safety”, “nutritional outcome”, 
“beneﬁ ts”, and “quality of life”. We identiﬁ ed several studies 
reporting mortality data after gastrostomy insertion in patients 
with amyotrophic lateral sclerosis, but only a handful directly 
compared survival time or 30-day post-procedure mortality after 
diﬀ erent methods of gastrostomy. In a meta-analysis of the data 
of the four studies that allowed within-study comparisons of 
percutaneous endoscopic gastrostomy versus radiologically 
inserted gastrostomy or per-oral image-guided gastrostomy, the 
diﬀ erence in 30-day mortality was increased by 2·1% for 
percutaneous endoscopic gastrostomy compared with the other 
insertion methods. However, the results of the meta-analysis did 
not provide robust evidence to indicate which method is safer 
because of an absence of within-study comparisons, diﬀ erences 
between populations, small sample sizes, and low event rates. 
The urgent need for prospective clinical trials in relation to the 
optimum method and timing for gastrostomy insertion, as well 
as the nutritional outcome for the patients, was highlighted in a 
Cochrane review on enteral tube feeding for amyotrophic lateral 
sclerosis and echoed in calls for more robust evidence by multiple 
organisations, such as the American Academy of Neurology and 
the European Federation of Neurological Societies.
Added value of this study
To our knowledge, ProGas is the ﬁ rst large, multicentre, 
longitudinal, cohort study to assess and compare the diﬀ erent 
methods of gastrostomy and explore the issue of optimal 
timing for gastrostomy insertion in patients with amyotrophic 
lateral sclerosis.
Implications of all the available evidence
In the absence of data from randomised trials, our ﬁ ndings 
might help neurologists, patients with amyotrophic lateral 
sclerosis, and the carers of patients with amyotrophic sclerosis 
to make decisions about the timing and method of 
gastrostomy. The next steps in building the evidence base must 
be to understand further the nutritional requirements of 
patients with amyotrophic lateral sclerosis, particularly the 
quantity and quality of nutriti onal support that patients receive 
after gastrostomy, and to explore the factors that can lead to 
continuing weight loss after the procedure.
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Statistical analysis
Assuming a 30-day mortality rate of 5%, based on a meta-
analysis of the available literature,8 to estimate mortality 
within greater or less than 2·5% (ie, 95% CI 2·5–7·5) 
would require 30-day mortality data for a minimum of 
300 patients with amyotrophic lateral sclerosis. Current 
European Federation of Neurological Societies guidelines 
recommend gastrostomy after weight loss of at least 10% 
from premorbid weight.14 This threshold was used in our 
study to classify patients into weight loss subgroups for 
subsequent analyses. Continuity corrected χ² tests were 
done to determine the diﬀ erence in the 30-day mortality 
and the complication rates after gastrostomy in patients 
who underwent percutaneous endoscopic gastrostomy, 
radiologically inserted gastrostomy, or per-oral image-
guided gastrostomy. Kaplan-Meier survival curves were 
used to determine the median survival time from 
placement and disease onset for the treatment groups. 
Cox proportional hazards regression analysis was done to 
determine predictors of survival from the time of 
gastrostomy insertion and from the time of disease onset 
(to take into account variables that have an eﬀ ect on 
survival over the whole course of the disease). Our 
rationale for inclusion of covariates in the Cox regression 
analysis was based on well known factors that might 
aﬀ ect survival in patients with amyotrophic lateral 
sclerosis as reported previously, and on our clinical 
judgment of other probable factors that might aﬀ ect 
survival post gastrostomy. Continuity corrected χ² tests 
were used to determine changes in nutritional status in 
the patients who underwent percutaneous endoscopic 
gastrostomy, radiologically inserted gastrostomy, or per-
oral image-guided gastrostomy. Cox proportional hazards 
regression analysis was also done to examine the eﬀ ect of 
nutritional status at 3 months post gastrostomy on 
subsequent survival. Cronbach’s α coeﬃ  cients were 
determined for the quality of life and strain measures 
used in the study to assess their internal consistency. A 
paired samples t test was used to determine diﬀ erences in 
the self-perceived quality of life of the patients and the 
strain of caregiving activities of carers. We obtained 
complete mortality data for all patients who underwent 
gastrostomy. Initially, complete case analysis was done—
ie, patients who had one or more missing values in the 
variables being analysed were omitted from the analysis 
pairwise. To compensate for missing data, post-hoc 
multiple imputation was done for the covariates of interest 
in our multiple regression analyses. Because ProGas was 
not a randomised controlled trial, we addressed the issue 
of treatment indication bias by undertaking a post-hoc 
propensity score analysis (appendix p 3).
Data were managed and analysed with SPSS Statistics 
for Windows version 21.0.
Role of the funding source
This study was supported jointly by the Motor Neurone 
Disease Association of England, Wales, and Northern 
Ireland and the Sheﬃ  eld Institute for Translational 
Neuroscience. Both funding bodies were consulted 
regarding the study design, and the decision to submit 
the report for publication fulﬁ ls their requirement for 
dissemination of the ﬁ ndings. However, the funding 
sources were not involved in data collection, data 
analysis, data interpretation, or writing of the report. All 
authors had full access to all of the data and CJM had 
ﬁ nal responsibility for the decision to submit the report 
for publication.
Results
Between Nov 2, 2010, and Jan 31, 2014, 330 patients 
underwent gastrostomy and were included in the 
analysis for the primary outcome (ﬁ gure 1). Table 1 
shows their baseline characteristics. 163 (49%) patients 
underwent percutaneous endoscopic gastrostomy, 
121 (37%) underwent radiologically inserted gastrostomy, 
43 (13%) underwent per-oral image-guided gastrostomy, 
and three (1%) underwent surgical gastrostomy. Table 2 
summarises the diﬀ erences across the three gastrostomy 
groups. Data for criteria used for gastrostomy method 
selection, indication, and predicted beneﬁ ts on Figure 1: Study proﬁ le
21 patients had unsuccessful 
 insertion at first attempt
309 patients had successful 
 insertion at first attempt
14 patients had successful 
 reinsertion
323 patients received 
 gastrostomy feeding (and 
 were included in the 
         analysis for the secondary 
         outcomes)
7 patients did not have 
 gastrostomy reinsertion 
attempt
330 patients underwent gastrostomy 
 (and were included in the analysis 
 for the primary outcome)
345 patients gave consent to enter 
 into the study (initial cohort)
15 patients did not undergo gastrostomy
 2 died before gastrostomy
 8 decided not to have it done
 5 did not undergo the procedure because preoperative 
  assessments deemed gastrostomy unsafe
484 patients referred for gastrostomy
139 patients excluded because of patient refusal,
         inability to consent, and logistical issues
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inﬂ uence of patients on timing of gastrostomy, and on 
types and sizes of gastrostomy tubes are available on 
appendix p 1.
The study was funded for 38 months and stopped on 
Jan 31, 2013, at which point all patients had undergone 
data collection for the primary outcome. Nine patients 
did not undergo formal 3-month assessments and 
93 patients did not undergo 12-month assessments.
12 (4%, 95% CI 2–6)  of 330 patients died within the 
ﬁ rst 30 days after gastrostomy: ﬁ ve (3%, 1–7) of 163 after 
percutaneous endoscopic gastrostomy, four (3%, 1–8) of 
121 after radiologically inserted gastrostomy, and three 
(7%, 2–19) of 43 after per-oral image-guided gastrostomy 
(p=0·46). We did not ﬁ nd evidence of a diﬀ erence in 30-
day mortality between the procedures after adjustment 
for case mix variables (age at onset, weight loss, 
functional decline rate, forced vital capacity, and site of 
onset) and treatment centre (appendix p 2).
Overall median survival after gastrostomy was 325 days 
(95% CI 289–361). Median survival time after per-
cutaneous endoscopic gastrostomy was 341 days (25th IQR 
inderteminate–164), after radiologically inserted gastro-
stomy was 361 days (25th IQR in der teminate–171), and 
after per-oral image-guided gastro stomy was 201 days 
(326–116; ﬁ gure 2). We noted some evidence of a diﬀ erence 
in survival times (log-rank χ² 1·4 on 2 df, p=0·03) between 
the three gastrostomy insertion methods before any 
adjustment for case mix variables (age at onset, weight 
loss, functional decline rate, forced vital capacity, and site 
of onset) and treatment centre. However, after adjustment 
for treatment centre and case mix variables, we did not 
note any evidence of a diﬀ erence in survival times between 
the three gastrostomy insertion methods (appendix p 2).
Irrespective of method of gastrostomy, among the 
12 patients who died within the ﬁ rst 30 days following 
the procedure, one patient (8%) had lost up to 10% of 
their bodyweight compared with that at diagnosis (2·6% 
loss), eight patients (67%) had lost more than 10% of 
their weight (mean 17·1% [SD 5·6]), one patient (8%) 
had gained weight (3·1% gain; χ², n=252, p=0·031), and 
for two patients (17%) weight data were missing. Binary 
logistic regression analysis showed that the odds for 
30-day mortality were 10·7 times higher (95% CI 1·3–87·0; 
p=0·027) for patients who had lost more than 10% of 
their weight from diagnosis compared with those who 
had lost 10% or less of weight.
Cox proportional hazards regression was done to 
ascertain the eﬀ ect of gastrostomy method on survival 
from the time of gastrostomy insertion, with adjustment 
for covariates that might also aﬀ ect survival. Variables that 
were inserted into the regression model were gastrostomy 
insertion method (percutaneous endoscopic gastrostomy, 
radiologically inserted gastrostomy, and per-oral image-
guided gastrostomy subgroups), forced vital capacity at 
the time of gastrostomy insertion, percentage of weight 
diﬀ erence at gastrostomy compared with diagnosis 
weight, and three additional well established predictors of 
survival in patients with amyotrophic lateral sclerosis:19 
age at the onset of amyotrophic lateral sclerosis, site of 
amyotrophic lateral sclerosis symptom onset (bulbar and 
limb subgroups), and monthly rate of decline of the 
revised amyotrophic lateral sclerosis functional rating 
Baseline value in all 
patients (n=330)
Age (years) 64·4 (11·7), n=315
Sex
Women 150/330 (45%)
Men 180/330 (55%)
Forced vital capacity (%) 62% (22·6), n=258
% Weight loss from diagnosis to baseline  (kg) 8·6 (9·8), n=252
ALSFRS-R score 28 (8·5), n=307
Body-mass index (kg/m2) 23·3 (4·4), n=274
Monthly ALSFRS-R decline 2·2% (1·7%), n=290
Disease duration from diagnosis (months) 16·7 (5·8–14·9), n=309
Non-invasive ventilation routine users 81/323 (25%)
Site of disease onset
Limb 152/324 (47%)
Bulbar 165/324 (51%)
Both limb and bulbar 6/324 (2%)
Respiratory 1/324 (0·3%)
Data are mean (SD), median (IQR), or n/N (%). ALSFRS-R=amyotrophic lateral 
sclerosis functional rating scale revised.
Table 1: Baseline demographic and clinical characteristics
PEG RIG PIG Statistic 
(n)
p value
Age (years) 64·2 (11·7), n=157 63·6 (9·8), n=114 67·2 (12·6), n=41 F (312) 0·200
Sex χ2 (327) 0·683
Women 73/163 (45%) 59/121 (49%) 18/43 (42%)
Men 90/163 (55%) 62/121 (51%) 25/43 (58%)
FVC (%) 65·4 (22·2), n=136 59 (23·1), n=87 52 (19·7), n=33 F (256) 0·004
% Weight loss from 
diagnosis to baseline 
(kg)
7·1 (8·5), n=117 8·7 (9·9), n=98 13 (12·3), n=35 F (250) 0·008
ALSFRS-R score 29·1 (8·2), n=152 27·7 (8·8), n=114 24·7 (7·9), n=39 F (305) 0·014
Body-mass index 
(kg/m2)
23·7 (4), n=135 23·4 (5·1), n=102 21·8 (3), n=34 F ( 271) 0·091
Monthly ALSFRS-R 
decline
2·1% (1·5), n=144 2·4% (2·1), n=105 2·1% (1·2), n=39 F (288) 0·302
NIV routine users 29/162 (18%) 23/118 (19%) 28/42 (67%) χ2 ( 322) 0·001
Site of disease onset χ2 (321) 0·369
Limb 74/161 (46%) 54/117 (46%) 23/43 (53%)
Bulbar 86/161 (53%) 59/117 (50%) 18/43 (42%)
Both limb and 
bulbar
1/161 (1%) 3/117 (3%) 2/43 (5%)
Respiratory 0/161 1/117 (1%) 0/43
Data are mean (SD) or n/N (%). PEG=percutaneous endoscopic gastrostomy. RIG=radiologically inserted gastrostomy. 
PIG=per-oral image-guided gastrostomy. F=one-way ANOVA F test. FVC=forced vital capacity. ALSFRS-R=amyotrophic 
lateral sclerosis functional rating scale revised. NIV=non-invasive ventilation.
Table 2: Baseline diﬀ erences of patients who underwent PEG, RIG, or PIG 
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scale (ALSFRS-R). The results showed that the hazard of 
death after gastrostomy insertion was signiﬁ cantly 
aﬀ ected by two main factors: the age at onset of 
amyotrophic lateral sclerosis (hazard ratio [HR] 1·032, 
95% CI 1·007–1·059; p=0·013) and the percentage of 
weight diﬀ erence at gastrostomy compared with weight at 
diagnosis (HR 0·956, 0·930–0·983; p=0·001). The hazard 
of death was not aﬀ ected by the gastrostomy insertion 
method. Figure 2 shows the survival functions for the 
subgroups of patients who underwent percutaneous 
endoscopic gastrostomy, radiologically inserted 
gastrostomy, or per-oral image-guided gastrostomy.
A Cox proportional hazards regression model including 
the same variables showed that the hazard of death from 
the time of amyotrophic lateral sclerosis onset was 
signiﬁ cantly aﬀ ected by the age at onset (HR 1·045 
[95% CI 1·015–1·075]; p=0·003), the ALSFRS-R monthly 
decline rate (1·768 [1·541–2·028]; p=0·001), and the site of 
amyotrophic lateral sclerosis symptom onset (bulbar 
compared with limb subgroups, HR 2·082 [1·204–3·601]; 
p=0·009).
To further explore the eﬀ ect of weight loss on survival 
after insertion, we did a Cox proportional hazards analysis 
with adjustment for covariates that might also aﬀ ect 
survival. The regression model included as variables 
weight at the time of gastrostomy compared with weight at 
diagnosis (<10% weight loss and >10% weight loss 
subgroups), forced vital capacity at the time of gastrostomy 
insertion, age at the onset of amyotrophic lateral sclerosis, 
site of amyotrophic lateral sclerosis symptom onset (bulbar 
and limb subgroups), and ALSFRS-R monthly decline 
rate. Hazard of death after gastrostomy insertion was 
signiﬁ cantly aﬀ ected by the age at onset (HR 1·035 [95% CI 
1·008–1·063]; p=0·011) and the percentage of weight loss 
from diagnosis to gastrostomy (>10% weight loss subgroup 
compared with the <10% weight loss subgroup, 2·514 
[1·490–4·243]; p=0·001). The median survival after 
gastrostomy for patients who had lost 10% or less of weight 
from diagnosis was 12 months (95% CI was indeterminate 
because survival was greater than 50% at the last timepoint 
in this subgroup) and for those who had lost more than 
10% of their weight from diagnosis was 7·7 months 
(n=223, 95% CI 6·5–8·9; log-rank test p=0·001). Figure 3 
shows the survival functions for the diﬀ erent subgroups of 
patients in terms of weight loss at gastrostomy compared 
with weight at the time of diagnosis.
Periprocedural complications did not diﬀ er signiﬁ cantly 
across the three gastrostomy insertion methods, apart 
from the higher perioperational distress experienced by 
percutaneous endoscopic gastrostomy patients (table 3). 
Table 4 summarises complications in the ﬁ rst 3 months 
after gastrostomy. Patients who received balloon- 
retention tubes (radiologically inserted gastrostomy) had 
a signiﬁ cantly higher rate of tube-related complications 
than did those who received bumper-retention tubes, 
including displacement (20 [31%] of 96 patients vs one 
[1%] of 154 patients; p=0·001), leakage (21 [22%] vs 16 
[10%]; p=0·011), replacement (29 [30%] vs four [3%]; 
p=0·001), and repeated gastrostomy (14/96 [15%] vs one 
[1%]; 0·001; appendix p 1); percutaneous endoscopic 
gastrostomy and per-oral image-guided gastrostomy odds 
ratio data are given in appendix p 1).
Valid weight measurements at 3 months after 
gastrostomy were collected for 170 (53%) of 323 patients, 
owing to attrition and diﬃ  culty in obtaining weight 
measurements from wheelchair-bound patients. After 
gastrostomy insertion, 43 (25%) of 170 patients gained 
more than 1 kg compared with weight at gastrostomy, 
43 (25%) had loss or gain of 1 kg or less compared with 
weight at gastrostomy, and 84 (49%) lost more than 1 kg 
compared to weight at gastrostomy. The method of 
Figure 2: Survival functions for patients who underwent PEG, RIG, or PIG
Subsequent Cox proportional hazards analysis suggested that the method of gastrostomy insertion was not 
signiﬁ cantly associated with survival. PEG=percutaneous endoscopic gastrostomy. RIG=radiologically inserted 
gastrostomy. PIG=per-oral image-guided gastrostomy. 
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gastrostomy insertion did not inﬂ uence the bodyweight 
post procedure (χ², n=170; p=0·082). In the 43 patients 
who gained weight, these gains were small (median 
weight gain compared with weight at gastrostomy 3·1 kg, 
IQR 1·8–6·5). Appendix p 6 shows the nutritional 
outcome for patients in terms of weight at 3 months 
compared with weight at diagnosis. Continuing weight 
loss at 3 months after gastrostomy was associated with 
poor survival (appendix p 2).
The diﬀ erences between patient quality of life at baseline 
and 3 months after gastrostomy were not statistically 
signiﬁ cant (mean [SD] total MQOL score 6·3 [1·6] at 
baseline vs 6·4 [1·6] at 3 months; p=0·749; appendix p 2). 
However, the strain of caregiving activities had increased 
signiﬁ cantly for carers at 3 months after gastrostomy 
(mean [SD] total MCSI score 9·9 [6·4] at baseline vs 11·8 
[6·5] at 3 months; p=0·001; appendix p 2).
The results of post-hoc multiple imputation and 
propensity score analyses of the survival endpoints 
suggested that our ﬁ ndings for 30-day mortality and 
predictors of survival were robust to both missing data and 
gastrostomy method preferences in the 24 participating 
sites (appendix pp 2, 3).
Discussion
In our study, 30-day mortality was similar for per-
cutaneous endoscopic gastrostomy, radiologically inserted 
gastrostomy, or per-oral image-guided gastrostomy, 
indicating that the three methods were as safe as each 
other in relation to procedure risk. The results suggested 
that weight loss at gastrostomy could aﬀ ect pro-
cedure outcome, although caution with interpretation is 
necessary because 30-day mortality was low in this cohort. 
Our data indicate that overall mortality after gastrostomy 
insertion is independent of the gastrostomy method and 
is driven by the patient age at the onset of amyotrophic 
lateral sclerosis and the percentage of weight loss from 
diagnosis to the timepoint of gastrostomy.
In terms of periprocedural complications, the three 
diﬀ erent methods of gastrostomy were similar apart 
from the increased rate of distress, related to procedure 
tolerance, experienced by patients who underwent 
percutaneous endoscopic gastrostomy. This ﬁ nding can 
be explained by the nature of the percutaneous 
endoscopic gastrostomy procedure, during which the 
patient’s throat is intubated with an endoscope and the 
gastrostomy tube is pulled through the mouth towards 
its placement site.20 Patients who underwent 
radiologically inserted gastrostomy had a signiﬁ cantly 
increased rate of gastrostomy tube-related complications. 
Perhaps this is not surprising, because radiologically 
inserted gastrostomy tubes are usually relatively narrow 
in diameter (10–14 Fr), have a balloon-retention system 
(balloons could burst or deﬂ ate, causing gastrostomy 
tubes to migrate or fall out), and are not as securely ﬁ xed 
as those inserted by percutaneous endoscopic 
gastrostomy or per-oral image-guided gastrostomy.
In terms of the nutritional outcome for the patient, 
gastrostomy feeding prevented further weight loss in only 
about half of the patients. In the 43 (25%) patients who 
gained weight, these gains were small and of doubtful 
clinical beneﬁ t. Continuing weight loss at 3 months after 
gastrostomy was associated with poor survival. The 
nutritional data suggested that the greater the percentage 
of weight loss at the time of gastrostomy from diagnosis, 
the less likely it was for patients to recover this loss after 
gastrostomy. This ﬁ nding was more evident for patients 
who at the time of gastrostomy had had more than 10% 
loss of their diagnosis weight; this subgroup of patients 
had also a signiﬁ cantly shorter survival compared with 
those who had lost up to 10% of their diagnosis weight. 
These results suggest that patients might beneﬁ t from 
early gastrostomy, before substantial weight loss that 
might not be reversible.
The reasons for the fairly poor nutritional outcome that 
we noted need further investigation. Perhaps weight loss 
due to continued denervation-induced skeletal muscle 
atrophy is masking nutritional beneﬁ ts,21,22 which could be 
related to the change in metabolic state. Patients with 
amyotrophic lateral sclerosis can present hypermetabolism, 
and the caloric requirements of patients after gastrostomy 
might have been underestimated such that their energy 
PEG RIG PIG Total p value
Overall complication rate 41/169 (24%) 20/121 (17%) 8/42 (19%) 69/332 (21%) 0·266
Diﬃ  cult procedure 26/168 (16%) 13/119 (11%) 7/42 (17%) 46/329 (14%) 0·475
Failed attempt 11/171 (6%) 7/125 (6%) 3/45 (7%) 21/341 (6%) 0·947
O₂ desaturation 6/166 (4%) 2/117 (2%) 3/42 (7%) 11/325 (3%) 0·241
Patient distress 26/166 (16%) 4/117 (3%) 2/42 (5%) 32/325 (10%) 0·002
Respiratory arrest 0/166 0/117 0/42 0/325 NA
Laryngeal spasm 2/166 (1%) 1/117 (1%) 0/42 3/325 (1%) 0·763
Haemorrhage 0/166 3/117 (3%) 0/42 3/325 (1%) 0·068
Numbers are patients who experienced each event (n)/total patients in each group (N). The periprocedural period is 
the time during the gastrostomy procedure. PEG=percutaneous endoscopic gastrostomy. RIG=radiologically inserted 
gastrostomy. PIG=per-oral image-guided gastrostomy. NA=not applicable.
Table 3: Periprocedural complications 
 PEG RIG PIG Total p value
Infection 20/129 (16%) 21/96 (22%) 3/25 (12%) 44/250 (18%) 0·745
Granulation tissue 15/129 (12%) 19/96 (20%) 3/25 (12%) 37/250 (15%) 0·214
Pain 25/129 (19%) 34/96 (35%) 10/25 (40%) 69/250 (28%) 0·010
Anxiety 10/129 (8%) 24/96 (25%) 1/25 (4%) 35/250 (14%) 0·001
Nausea 12/129 (9%) 10/96 (10%) 2/25 (8%) 24/250 (10%) 0·923
Diarrhoea 6/129 (5%) 10/96 (10%) 3/25 (12%) 19/250 (8%) 0·185
Pneumonia 4/129 (3%) 4/96 (4%) 4/25 (16%) 12/250 (5%) 0·021
Constipation 16/129 (13%) 22/96 (24%) 9/25 (36%) 47/250 (19%) 0·010
Fatigue 15/129 (12%) 23/96 (24%) 4/25 (16%) 42/250 (17%) 0·050
Numbers are patients who experienced each event (n)/total patients in each group (N). The postprocedural period is 
the ﬁ rst 3 months after the completion of the gastrostomy procedure. PEG=percutaneous endoscopic gastrostomy. 
RIG=radiologically inserted gastrostomy. PIG=per-oral image-guided gastrostomy.
Table 4: Postprocedural complications
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intake was lower than energy expenditure.23 A small phase 
2 study showed a potential beneﬁ t in terms of survival and 
nutritional gains for patients fed high caloriﬁ c diets 
through a percutaneous endoscopic gastrostomy tube.24 
Therefore, further study and subsequent evidence-based 
guidance on nutritional management post gastrostomy 
tube insertion is needed. A further potential metabolic 
explanation for our ﬁ ndings is related to the concept of 
refractory cachexia. The body of a patient with cachexia 
(deﬁ ned as weight loss of more than 5%) is recognised to 
undergo irreparable metabolic changes, making artiﬁ cial 
nutritional support ineﬀ ective.25 This idea is well recognised 
in oncology but has not been explored in patients with 
amyotrophic lateral sclerosis.
The eﬀ ect of gastrostomy on the quality of life of patients 
in our study seemed to be neutral. Conversely, the strain of 
caregiving activities increased signiﬁ cantly after 
gastrostomy, although this was independent of insertion 
method. However, consequences of amyotrophic lateral 
sclerosis including increasing motor disability and 
dependency might contribute to caregiver strain. These 
results highlight the importance of provision of 
information and support from health-care professionals to 
carers, as well as to patients, before and after gastrostomy.
This study has limitations. This study was not a 
randomised controlled trial and the assignment of 
patients to a speciﬁ c gastrostomy method was not done at 
random, but based on practical and clinical considerations. 
Therefore we can make associations but we are limited in 
the ability to draw conclusions with regard to the direct 
eﬀ ects of gastrostomy on survival and nutritional 
outcome compared with not having had a gastrostomy. 
Another limitation is that, of 484 patients who had been 
referred for a gastrostomy in the 24 participating centres, 
we recruited 345 patients (participation rate 71%). Patient 
refusal and several logistical issues hindered full 
recruitment. Unfortunately, we could not obtain 
meaningful information for the potential participants 
who were not recruited to our study because we did not 
have the consent of these patients to do so, and we could 
not compare their characteristics with those of patients in 
this study. Practical diﬃ  culties in obtaining weight 
measurements at 3 months after gastrostomy introduced 
another limitation. The prospective element of this study 
allowed us to follow up a large number of patients after 
gastrostomy insertion and to consistently collect data 
related to the predetermined primary and secondary 
outcomes. A major strength of this study is that our 
sample is representative of the wider amyotrophic lateral 
sclerosis population: the baseline characteristics of the 
patients who took part are very similar to those of other 
reported cohorts of patients with amyotrophic lateral 
sclerosis.19,26
We noted signiﬁ cantly worse respiratory impairment in 
the per-oral image-guided gastrostomy group. Despite 
this, 30-day mortality was similar to the other groups. 
This observation would suggest that percutaneous 
endoscopic gastrostomy might be the optimum method of 
gastrostomy when respiratory function is largely 
unimpaired and per-oral image-guided gastrostomy when 
respiratory function is signiﬁ cantly compromised. Both 
percutaneous endoscopic gastrostomy and per-oral image-
guided gastrostomy seemed to oﬀ er easier post-insertion 
tube management than radiologically inserted 
gastrostomy; ease of management is crucial, especially in 
very frail patients who undergo gastrostomy late, when 
they are more likely to feel the burden of other 
consequences of amyotrophic lateral sclerosis, such as 
respiratory problems and the loss of mobility and speech.
Our study showed that delay might lead to diminishing 
gains, especially for patients who at the time of gastrostomy 
have experienced excessive weight loss from their diagnosis 
weight. From a safety and eﬃ  cacy perspective, the current 
guidelines of 10% weight loss might not be ideal and 
perhaps a better threshold would be to recommend 
gastrostomy insertion at a threshold similar to the one for 
cachexia—ie, at roughly 5% weight loss. Another recently 
suggested approach is to consider gastrostomy based on the 
ability of an individual to meet their total daily energy 
requirements.27 Delay of gastrostomy until after weight loss 
of more than 10% might convey minimal clinically 
meaningful beneﬁ t. However, some patients will not wish 
to undergo early gastrostomy. For such patients, gastrostomy 
will still have a role alleviating the diﬃ  culties caused by 
advanced dysphagia—eg, to allow administration of drugs 
and hydration—but in view of the possible diminishing 
nutritional beneﬁ ts of delayed gastrostomy, other options of 
palliative support should also be considered.
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